Table 3 Regression analyses of the association between adoption of CDC HIV pre-test counseling guidelines and offer of on-site vs. Off-site HCV testing
Off-site HCV testinga | On-site HCV testing | P-value | Unadjusted Odds Ratio (95 % CI)b | Adjusted Odds Ratio (95 % CI)b | |
|---|---|---|---|---|---|
State-level legislation enables eliminating HIV pretest counseling requirement | <0.01 | ||||
No | 42 (31.3) | 92 (68.7) | 1 | 1 | |
Yes | 106 (59.2) | 73 (40.8) | 0.31 (0.20, 0.50) | 1.65 (0.32, 8.46) | |
Prevalence of injection drug users | 0.06 | ||||
< 25 % | 57 (57.0) | 43 (43.0) | 1 | 1 | |
25-74 % | 57 (41.6) | 80 (58.4) | 1.86 (1.10, 3.14) | 2.68 (1.11, 6.47) | |
≥ 75 % | 33 (46.5) | 38 (53.5) | 1.53 (0.83, 2.82) | 0.69 (0.24, 2.01) | |
African-American patients | 0.49 | ||||
< 10 % | 73 (49.3) | 75 (50.7) | 1 | 1 | |
≥ 10 % | 75 (45.4) | 90 (54.6) | 1.17 (0.75, 1.82) | 0.97 (0.41, 2.30) | |
Hispanic patients | 0.70 | ||||
< 10 % | 75 (48.4) | 80 (51.6) | 1 | 1 | |
≥ 10 % | 73 (46.2) | 85 (53.8) | 1.09 (0.70, 1.70) | 1.26 (0.50, 3.16) | |
Revenue from federal government | 0.01 | ||||
None | 114 (51.8) | 106 (48.2) | 1 | 1 | |
≥ 1 % | 33 (36.6) | 59 (63.4) | 1.87 (1.13, 3.07) | 2.47 (1.04, 5.88) | |
Revenue from private insurance | 0.11 | ||||
None | 80 (43.5) | 104 (56.5) | 1 | 1 | |
≥ 1 % | 48 (52.7) | 61 (47.3) | 0.69 (0.44, 1.08) | 1.33 (0.59, 2.98) | |
Human resources | |||||
Log Staff-to-patient ratio, mean (SD) | -3.40 (0.78) | -3.24 (0.66) | 0.05 | 1.36 (0.99, 1.88) | 1.80 (1.10, 2.93) |
CARF accreditation | 0.21 | ||||
No | 76 (51.0) | 73 (49.0) | 1 | 1 | |
Yes | 72 (43.9) | 97 (56.1) | 1.33 (0.85, 2.08) | 1.37 (0.60, 3.12) | |
Ownership | <0.01 | ||||
Private not-for-profit | 77 (52.0) | 71 (48.0) | 1 | 1 | |
Private for profit | 61 (50.4) | 60 (49.6) | 1.07 (0.66, 1.73) | 1.52 (0.66, 3.46) | |
Public | 10 (22.7) | 34 (77.3) | 3.69 (1.70, 8.02) | 3.36 (0.95, 11.9) | |
Hospital affiliation | <0.01 | ||||
No | 134 (51.3) | 127 (48.6) | 1 | 1 | |
Yes | 14 (26.9) | 38 (73.1) | 2.86 (1.48, 5.54) | 6.22 (2.04, 18.9) | |
Methods of treatment | <0.01 | ||||
Methadone only | 69 (40.1) | 103 (59.9) | 1 | 1 | |
Buprenorphine only | 55 (75.3) | 18 (24.7) | 0.22 (0.12, 0.41) | 0.17 (0.06, 0.49) | |
Methadone + Buprenorphine | 24 (35.3) | 44 (64.7) | 1.23 (0.68, 2.20) | 2.95 (1.19, 7.31) | |
Time | <0.01 | ||||
2005 | 38 (27.7) | 99 (72.3) | 1 | 1 | |
2011 | 110 (62.5) | 66 (37.5) | 0.23 (0.14, 0.37) | 0.10 (0.02, 0.45) | |
N | 148 (47.3) | 165 (52.7) | 313 | 282c | |